These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

52 related items for PubMed ID: 3150268

  • 1. Effects of synthetic analogues of platelet-activating factor (PAF) on fibrinolytic activity in the rat.
    Hofmann B, Meisgeier U, Kertscher P, Ostermann G.
    Biomed Biochim Acta; 1988; 47(10-11):S161-4. PubMed ID: 3150268
    [Abstract] [Full Text] [Related]

  • 2. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. I. Studies on blood platelets in vitro.
    Ostermann G, Hofmann B, Kertscher HP, Till U.
    J Lipid Mediat; 1990; 2(1):21-31. PubMed ID: 1966804
    [Abstract] [Full Text] [Related]

  • 3. Platelet-stimulating and membranolytic properties of racemic PAF-acether and analogues.
    Ostermann G, Kertscher HP, Till U.
    Biomed Biochim Acta; 1985; 44(2):K17-23. PubMed ID: 4004829
    [Abstract] [Full Text] [Related]

  • 4. Enhanced vascular plasminogen activator (t-PA) release by epinephrine in aged rats.
    Iacoviello L, D'Adamo MC, De Curtis A, Buczko W, Donati MB.
    Thromb Haemost; 1995 May; 73(5):841-4. PubMed ID: 7482413
    [Abstract] [Full Text] [Related]

  • 5. Effect of specific antagonists on PAF-induced platelet aggregation and release of plasminogen activator.
    Hofmann B, Ostermann G, Hoffmann A, Klöcking HP, Kertscher HP.
    Biomed Biochim Acta; 1988 May; 47(10-11):S157-60. PubMed ID: 3248103
    [Abstract] [Full Text] [Related]

  • 6. Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets.
    Hofmann B, Ostermann G, Kertscher HP, Till U.
    Thromb Res; 1988 Feb 15; 49(4):415-23. PubMed ID: 3381200
    [Abstract] [Full Text] [Related]

  • 7. Fibrinolytic activity in blood is distributed over a cellular and the plasma fraction which can be modulated separately.
    van Giezen JJ, Chung-A-Hing JE, Vegter CB, Bouma BN, Jansen JW.
    Thromb Haemost; 1994 Dec 15; 72(6):887-92. PubMed ID: 7740459
    [Abstract] [Full Text] [Related]

  • 8. The role of cyclic nucleotides in the release of tissue-type plasminogen activator and von Willebrand factor.
    Tranquille N, Emeis JJ.
    Thromb Haemost; 1993 Mar 01; 69(3):259-61. PubMed ID: 8097063
    [Abstract] [Full Text] [Related]

  • 9. Platelet-activating factor and WEB-2086 directly modulate rat cardiomyocyte contractility.
    Delbridge LM, Stewart AG, Goulter CM, Morgan TO, Harris PJ.
    J Mol Cell Cardiol; 1994 Feb 01; 26(2):185-93. PubMed ID: 8006979
    [Abstract] [Full Text] [Related]

  • 10. Platelet-activating factor stimulates phosphatidic acid formation in cultured rat mesangial cells: roles of phospholipase D, diglyceride kinase, and de novo phospholipid synthesis.
    Kester M.
    J Cell Physiol; 1993 Aug 01; 156(2):317-25. PubMed ID: 8393878
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effect of ether lipid 1-O-octadecyl-2-O-methoxy-rac-glycero-3-phosphocholine and its analogues platelet activating factor and carbamyl-platelet activating factor on the biosynthesis of interleukin-6 in human thymic epithelial cells cultivated in vitro.
    Cardile V, Mascarucci P, De Simoni MG, Jiang X, Bindoni M.
    Cytokine; 1996 Sep 01; 8(9):698-701. PubMed ID: 8932980
    [Abstract] [Full Text] [Related]

  • 13. Biochemical characterization of the interaction of lipid phosphoric acids with human platelets: comparison with platelet activating factor.
    Sugiura T, Tokumura A, Gregory L, Nouchi T, Weintraub ST, Hanahan DJ.
    Arch Biochem Biophys; 1994 Jun 01; 311(2):358-68. PubMed ID: 8203898
    [Abstract] [Full Text] [Related]

  • 14. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J.
    J Pharmacol Exp Ther; 1997 Jan 01; 280(1):114-21. PubMed ID: 8996188
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of ether lipid 1-O-octadecyl-2-methoxy-rac-glycero- 3-phosphocholine and its analogs PAF and CPAF on the release of nitric oxide in primary cultures of rat astrocytes.
    Cardile V, Jiang X, Renis M, Bindoni M.
    Brain Res; 1996 Apr 09; 715(1-2):98-103. PubMed ID: 8739627
    [Abstract] [Full Text] [Related]

  • 17. [PAF-antagonists with a phospholipid structure. 1. Phospholipids with hetero-arene head groups: synthesis, characterization and determination of the action of structural elements].
    Kertscher HP, Ostermann G, Findeisen M, Limmer S, Gawrisch K.
    Pharmazie; 1991 Aug 09; 46(8):575-9. PubMed ID: 1798710
    [Abstract] [Full Text] [Related]

  • 18. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S.
    Dan Med Bull; 1993 Sep 09; 40(4):383-408. PubMed ID: 8222763
    [Abstract] [Full Text] [Related]

  • 19. [Interaction of 1-O-alkyl-2-methoxy-sn-glycero-3-phosphocholine and platelet activating factor with blood and tumor cells].
    Muzia GI, Orlov SM, Berdyshev EV, Kulikov VI.
    Biokhimiia; 1994 Jul 09; 59(7):1054-61. PubMed ID: 7948414
    [Abstract] [Full Text] [Related]

  • 20. Endotoxin-induced pulmonary leukostasis in the rat: role of platelet-activating factor and tumor necrosis factor.
    Chang SW.
    J Lab Clin Med; 1994 Jan 09; 123(1):65-72. PubMed ID: 8288963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.